New hope for advanced breast cancer: trial tests alternative drug combo
NCT ID NCT03264547
Summary
This study compared two different three-drug combinations for treating advanced or returning HER2-positive breast cancer. Researchers tested whether adding eribulin to standard drugs works as well as adding taxane chemotherapy, while aiming for fewer side effects like numbness. The trial involved 446 women with this specific cancer type who hadn't received certain prior treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Kanagawa Cancer Center
Yokohama, Kanagawa, 241-8515, Japan
-
National Hospital Organization Osaka National Hospital
Osaka, Osaka, 540-0006, Japan
Conditions
Explore the condition pages connected to this study.